About Tomophase
Tomophase is a company based in Cambridge (United States) founded in 2003 was acquired by Guangdongwinstarmedicalscience in April 2014. Tomophase has raised $4.5 million across 1 funding round from investors including Sanderling Ventures and Guangdongwinstarmedicalscience. Tomophase operates in a competitive market with competitors including Polarean Imaging, Imbio, Fluidda, Cyclopharm and Bioxydyn, among others.
- Headquarter Cambridge, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
- Legal Name Tomophase Corporation
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$4.5 M (USD)
in 1 rounds
-
Latest Funding Round
$4.5 M (USD), Series A
Dec 05, 2005
-
Investors
Sanderling Ventures
& 1 more
-
Employee Count
Not available
-
Acquired by
Guangdongwinstarmedicalscience
(Apr 18, 2014)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Tomophase
Tomophase has successfully raised a total of $4.5M through 1 strategic funding round. The most recent funding activity was a Series A round of $4.5 million completed in December 2005. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Tomophase
Tomophase has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Sanderling Ventures and Guangdongwinstarmedicalscience.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Biomedical investment financing and active management services.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Tomophase
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Tomophase
Investment portfolio details for Tomophase
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Tomophase
Detailed financials for Tomophase
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Tomophase Comparisons
Peer comparison for Tomophase
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Tomophase
Tomophase operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Polarean Imaging, Imbio, Fluidda, Cyclopharm and Bioxydyn, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Noble gas polarizers for hyperpolarized pulmonary MRI are developed.
|
|
| Locked | Locked | Locked |
Medical imaging analysis for respiratory clinical support is provided.
|
|
| Locked | Locked | Locked |
Functional respiratory imaging and contract research services are provided.
|
|
| Locked | Locked | Locked |
Medical devices and radiopharmaceuticals for lung imaging are developed.
|
|
| Locked | Locked | Locked |
MRI-based diagnostic imaging services for respiratory disorders are offered.
|
Detailed competitors of Tomophase
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Tomophase
Complete news archive for Tomophase
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Tomophase
Tomophase was founded in 2003 and raised its 1st funding round 2 years after it was founded.
Tomophase is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Tomophase is a funded company, having raised a total of $4.5M across 1 funding round to date.
Tomophase was founded in 2003 in Cambridge, United States, within the medical devices sector. Endoscopic devices for respiratory disorders are developed, utilizing a proprietary platform based on optical interferometry with near-infrared radiation. The flagship product, Tomophase OCTIS, provides real-time in vivo imaging of bronchial and pulmonary tissue to identify damage. FDA 510(k) clearance has been obtained for this system.
Tomophase's top competitors include Fluidda, Polarean Imaging and Imbio.
Tomophase has 2 investors. Key investors include Sanderling Ventures, and Guangdongwinstarmedicalscience.